8-K Announcements
6Material company update
Apr 7, 2026·SEC
Material company update
Mar 24, 2026·SEC
Material company update
Mar 16, 2026·SEC
Fennec Pharmaceuticals Inc.(FENC)Earnings, Financials & Key Ratios
FENC•NASDAQ
$6.90
$194M mkt cap·Price updated May 7, 2026
AboutFennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.Show more
- Revenue$48M+123.7%
- EBITDA$3M+127.0%
- Net Income-$436K+97.3%
- EPS (Diluted)-0.02+97.3%
- Gross Margin93.3%-0.8%
- EBITDA Margin7.08%+112.1%
- Operating Margin5.4%+109.0%
- Net Margin-0.92%+98.8%
- Interest Coverage0.63+116.8%
FENC Key Insights
Fennec Pharmaceuticals Inc. (FENC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 56.8% free cash flow margin
- ✓Efficient asset utilization: 1.1x turnover
✗Weaknesses
- ✗Weak momentum: RS Rating 17 (bottom 17%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
FENC Price & Volume
Fennec Pharmaceuticals Inc. (FENC) stock price & volume — 10-year historical chart
Loading chart...
FENC Growth Metrics
Fennec Pharmaceuticals Inc. (FENC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-21.82%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-474.92%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-142.4%
Return on Capital
10 Years-94.33%
5 Years-61.79%
3 Years-51.02%
Last Year8.96%
FENC Recent Earnings
Fennec Pharmaceuticals Inc. (FENC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
Mar 24, 2026EPS
$0.11
Est $0.03
-466.7%
Revenue
$14M
Est $15M
-5.8%
Q4 2025
Nov 13, 2025EPS
$0.02
Est $0.08
+75.0%
Revenue
$12M
Est $15M
-15.2%
Q3 2025
Aug 14, 2025EPS
$0.11
Est $0.06
-83.3%
Revenue
$10M
Est $10M
+0.9%
Q2 2025
May 13, 2025EPS
$0.04
Est $0.12
+66.7%
Revenue
$9M
Est $9M
-3.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 24, 2026 | $0.11vs $0.03-466.7% | $14Mvs $15M-5.8% |
| Q4 2025 | Nov 13, 2025 | $0.02vs $0.08+75.0% | $12Mvs $15M-15.2% |
| Q3 2025 | Aug 14, 2025 | $0.11vs $0.06-83.3% | $10Mvs $10M+0.9% |
| Q2 2025 | May 13, 2025 | $0.04vs $0.12+66.7% | $9Mvs $9M-3.2% |
Based on last 12 quarters of dataView full earnings history →
FENC Peer Comparison
Fennec Pharmaceuticals Inc. (FENC) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 LCTX | 333.08M | 1.37 | -4.89 | 53.24% | -436.47% | -134.53% | 0.06 | |
 SNOA | 2.04M | 1.18 | -0.42 | 12.19% | -19.02% | -98.19% | 0.07 | |
 HALO | 7.68B | 65.19 | 25.46 | 37.55% | 22.69% | 6.49% | ||
 SUPN | 3.01B | 52.28 | -76.88 | 8.63% | -3.74% | -2.73% | 0.04 | |
 PTCT | 5.35B | 64.49 | 8.29 | 114.51% | -22.58% | |||
 RCKT | 397.53M | 3.67 | -1.83 | -80.49% | 0.09 | |||
 RARE | 2.57B | 26.13 | -4.48 | 20.13% | -91.03% | -6.08% | ||
 JAZZ | 14.24B | 226.96 | -38.86 | 4.88% | 0.66% | 0.71% | 1.26 |
Compare FENC vs Peers
Fennec Pharmaceuticals Inc. (FENC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
FENC Income Statement
Fennec Pharmaceuticals Inc. (FENC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 170K | 0 | 1.47M | 21.25M | 47.54M | 38.79M |
| Revenue Growth % | - | - | - | - | - | -100% | - | 1341.62% | 123.69% | -21.82% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 82.59K | 1.26M | 3.18M | 2.67M |
| COGS % of Revenue | - | - | - | - | - | - | 5.6% | 5.92% | 6.7% | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 170K▲ 0% | 0▼ 100.0% | 1.39M▲ 0% | 19.99M▲ 1336.7% | 44.35M▲ 121.8% | 36.12M▲ 0% |
| Gross Margin % | - | - | - | - | 100% | - | 94.4% | 94.08% | 93.3% | 93.12% |
| Gross Profit Growth % | - | - | - | - | - | -100% | - | 1336.71% | 121.85% | - |
| Operating Expenses | 2.87M | 6.95M | 10.41M | 13.31M | 18.05M | 17.07M | 23.09M | 32.76M | 41.79M | 40.78M |
| OpEx % of Revenue | - | - | - | - | 10620.59% | - | 1565.99% | 154.17% | 87.9% | - |
| Selling, General & Admin | 2.4M | 5.01M | 5.4M | 7.57M | 12.95M | 12.13M | 19.69M | 32.71M | 41.48M | 40.5M |
| SG&A % of Revenue | - | - | - | - | 7617.65% | - | 1335.96% | 153.91% | 87.25% | - |
| Research & Development | 472K | 1.94M | 5.01M | 5.74M | 5.11M | 4.94M | 3.39M | 56K | 307K | 280K |
| R&D % of Revenue | - | - | - | - | 3002.94% | - | 230.03% | 0.26% | 0.65% | - |
| Other Operating Expenses | -14K | -8K | 6K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -2.87M▲ 0% | -6.95M▼ 142.1% | -10.41M▼ 49.7% | -13.31M▼ 27.9% | -17.89M▼ 34.4% | -17.07M▲ 4.5% | -21.69M▼ 27.1% | -12.77M▲ 41.1% | 2.57M▲ 120.1% | -4.66M▲ 0% |
| Operating Margin % | - | - | - | - | -10520.59% | - | -1471.6% | -60.09% | 5.4% | -12.02% |
| Operating Income Growth % | -51.9% | -142.11% | -49.75% | -27.88% | -34.36% | 4.55% | -27.08% | 41.13% | 120.11% | - |
| EBITDA | 0 | 0 | 0 | -13.07M | 0 | -17.07M | -21.69M | -12.48M | 3.37M | -4.54M |
| EBITDA Margin % | - | - | - | - | - | - | -1471.47% | -58.74% | 7.08% | -11.69% |
| EBITDA Growth % | 100% | - | - | - | 100% | - | -27.09% | 42.45% | 126.98% | -279.14% |
| D&A (Non-Cash Add-back) | 2.87M | 6.95M | 10.41M | 0 | 17.89M | 0 | 0 | 287K | 800K | 127K |
| EBIT | -2.76M | -7.3M | -9.38M | -13.07M | -17.89M | -17.07M | -21.69M | -12.65M | 4M | -4.35M |
| Net Interest Income | 0 | 0 | 0 | 322.32K | 91.59K | -72K | -783K | -2.95M | -2.48M | -1.84M |
| Interest Income | 0 | 0 | 0 | 322.32K | 91.59K | 54K | 195K | 441K | 1.59M | 935.1K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 126K | 978K | 3.39M | 4.07M | 2.77M |
| Other Income/Expense | 82K | -95K | 521K | 239.44K | -224K | -121.92K | -1.08M | -3.27M | -2.64M | -1.91M |
| Pretax Income | -2.79M▲ 0% | -7.05M▼ 152.6% | -9.89M▼ 40.3% | -13.07M▼ 32.2% | -18.11M▼ 38.5% | -17.19M▲ 5.1% | -22.77M▼ 32.5% | -16.05M▲ 29.5% | -71K▲ 99.6% | -6.58M▲ 0% |
| Pretax Margin % | - | - | - | - | -10652.35% | - | -1544.89% | -75.5% | -0.15% | -16.95% |
| Income Tax | -8K | -47K | -348K | 0 | 0 | 0 | 0 | 0 | 365K | 365K |
| Effective Tax Rate % | 0.29% | 0.67% | 3.52% | 0% | 0% | 0% | 0% | 0% | -514.08% | -5.55% |
| Net Income | -2.79M▲ 0% | -7.05M▼ 152.6% | -9.89M▼ 40.3% | -13.07M▼ 32.2% | -18.11M▼ 38.5% | -17.19M▲ 5.1% | -22.77M▼ 32.5% | -16.05M▲ 29.5% | -436K▲ 97.3% | -6.94M▲ 0% |
| Net Margin % | - | - | - | - | -10652.35% | - | -1544.89% | -75.5% | -0.92% | -17.89% |
| Net Income Growth % | -323.22% | -152.64% | -40.33% | -32.2% | -38.53% | 5.06% | -32.46% | 29.55% | 97.28% | -474.92% |
| Net Income (Continuing) | -2.76M | -7.3M | -9.38M | -13.07M | -18.11M | -17.19M | -22.77M | -16.05M | -436K | -6.94M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.22▲ 0% | -0.47▼ 113.6% | -0.52▼ 10.6% | -0.63▼ 21.2% | -0.76▼ 20.6% | -0.67▲ 11.8% | -0.95▼ 41.8% | -0.60▲ 36.8% | -0.02▲ 97.3% | -0.25▲ 0% |
| EPS Growth % | -261.25% | -113.64% | -10.64% | -21.15% | -20.63% | 11.84% | -41.79% | 36.84% | 97.33% | -142.4% |
| EPS (Basic) | -0.22 | -0.47 | -0.52 | -0.63 | -0.76 | -0.67 | -0.95 | -0.60 | -0.02 | - |
| Diluted Shares Outstanding | 12.77M | 15.01M | 19.02M | 19.9M | 23.7M | 26.01M | 26.27M | 26.57M | 27.29M | 27.89M |
| Basic Shares Outstanding | 12.68M | 14.99M | 18.94M | 19.9M | 23.7M | 26.01M | 26.27M | 26.57M | 27.29M | 27.89M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
FENC Balance Sheet
Fennec Pharmaceuticals Inc. (FENC) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 3.97M | 28.4M | 22.95M | 13.88M | 31.42M | 22.39M | 26.73M | 26.86M | 44.12M | 46.02M |
| Cash & Short-Term Investments | 3.93M | 28.26M | 22.78M | 13.65M | 30.34M | 21.1M | 23.77M | 13.27M | 26.63M | 21.93M |
| Cash Only | 3.93M | 28.26M | 22.78M | 13.65M | 30.34M | 21.1M | 23.77M | 13.27M | 26.63M | 21.93M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 1.54M | 8.81M | 12.88M | 19.32M |
| Days Sales Outstanding | - | - | - | - | - | - | 382.54 | 151.38 | 98.92 | 153.28 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 576K | 2.16M | 1.06M | 2.47M |
| Days Inventory Outstanding | - | - | - | - | - | - | 2.55K | 625.05 | 121.51 | 244.09 |
| Other Current Assets | 3K | 13K | 1K | 8K | 276K | 253K | 63K | 44K | 466K | 897.12K |
| Total Non-Current Assets | 0 | 0 | 0 | 262K | 0 | 27K | 211K | 6K | 822K | 3.19M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.77M |
| Other Non-Current Assets | 0 | 0 | 0 | 262K | 0 | 27K | 211K | 6K | 822K | 5.75M |
| Total Assets | 3.97M▲ 0% | 28.4M▲ 615.0% | 22.95M▼ 19.2% | 14.15M▼ 38.4% | 31.42M▲ 122.1% | 22.41M▼ 28.7% | 26.94M▲ 20.2% | 26.86M▼ 0.3% | 44.95M▲ 67.3% | 49.21M▲ 0% |
| Asset Turnover | - | - | - | - | 0.01x | - | 0.05x | 0.79x | 1.06x | 0.84x |
| Asset Growth % | 289.79% | 615.03% | -19.19% | -38.36% | 122.09% | -28.66% | 20.19% | -0.28% | 67.31% | -11.05% |
| Total Current Liabilities | 402K | 1.64M | 1.64M | 2.27M | 2.35M | 1.65M | 4.61M | 7.55M | 6.92M | 9.81M |
| Accounts Payable | 244K | 855K | 1.03M | 1.61M | 1.57M | 777K | 2.39M | 3.78M | 3.24M | 5.86M |
| Days Payables Outstanding | - | - | - | - | - | - | 10.56K | 1.1K | 371.53 | 694.8 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 495.76K |
| Other Current Liabilities | 33K | 167K | 0 | 0 | 0 | 0 | 0 | 0 | 248K | 3.7M |
| Current Ratio | 9.88x | 17.28x | 14.02x | 6.11x | 13.39x | 13.54x | 5.80x | 3.56x | 6.38x | 6.38x |
| Quick Ratio | 9.88x | 17.28x | 14.02x | 6.11x | 13.39x | 13.54x | 5.67x | 3.27x | 6.22x | 6.22x |
| Cash Conversion Cycle | - | - | - | - | - | - | -7.63K | -318.86 | -151.1 | -297.42 |
| Total Non-Current Liabilities | 244K | 855K | 1.03M | 0 | 0 | 4.99M | 24.9M | 30.93M | 43.9M | 43.9M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 4.99M | 24.9M | 30.93M | 19.34M | 18.09M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24.56M | 50.39M |
| Total Liabilities | 402K | 1.64M | 1.64M | 2.27M | 2.35M | 6.64M | 29.51M | 38.49M | 50.82M | 53.7M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 4.99M | 24.9M | 30.95M | 19.34M | 18.09M |
| Net Debt | -3.93M | -28.26M | -22.78M | -13.65M | -30.34M | -16.11M | 1.13M | 17.68M | -7.29M | -3.84M |
| Debt / Equity | - | - | - | - | - | 0.32x | - | - | - | -4.03x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 5.74x | -3.99x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | -2.17x | -2.17x |
| Interest Coverage | - | - | - | - | - | -135.49x | -22.18x | -3.76x | 0.63x | -1.57x |
| Total Equity | 3.57M▲ 0% | 26.76M▲ 649.5% | 21.31M▼ 20.3% | 11.88M▼ 44.3% | 29.07M▲ 144.8% | 15.77M▼ 45.7% | -2.57M▼ 116.3% | -11.62M▼ 352.4% | -5.87M▲ 49.5% | -4.49M▲ 0% |
| Equity Growth % | 551.46% | 649.5% | -20.35% | -44.28% | 144.8% | -45.74% | -116.29% | -352.39% | 49.48% | -682.36% |
| Book Value per Share | 0.28 | 1.78 | 1.12 | 0.60 | 1.23 | 0.61 | -0.10 | -0.44 | -0.22 | -0.16 |
| Total Shareholders' Equity | 3.57M | 26.76M | 21.31M | 11.88M | 29.07M | 15.77M | -2.57M | -11.62M | -5.87M | -4.49M |
| Common Stock | 74.52M | 103.05M | 106.39M | 106.39M | 140.73M | 140.8M | 142.59M | 144.31M | 145.61M | 147.51M |
| Retained Earnings | -114.32M | -121.37M | -131.26M | -144.03M | -162.14M | -179.49M | -203.2M | -219.25M | -219.68M | -224.42M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 1.24M | 1.24M | 1.24M | 1.24M | 1.24M | 1.24M | 1.24M | 1.24M | 1.24M | 1.24M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
FENC Cash Flow Statement
Fennec Pharmaceuticals Inc. (FENC) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -2.12M | -3.64M | -7.83M | -9.06M | -15.6M | -14.22M | -18.06M | -17.14M | 26.98M | 26.98M |
| Operating CF Margin % | - | - | - | - | -9173.53% | - | -1224.95% | -80.67% | 56.75% | - |
| Operating CF Growth % | -14.07% | -71.42% | -114.94% | -15.77% | -72.13% | 8.8% | -26.97% | 5.07% | 257.38% | 182.34% |
| Net Income | -2.79M | -7.05M | -9.89M | -12.78M | -18.11M | -17.35M | -23.71M | -16.05M | -436K | -6.94M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 16K | 149K | 287K | 959K | 236K |
| Stock-Based Compensation | 615K | 1.52M | 1.82M | 2.67M | 2.79M | 4.01M | 4.22M | 5.35M | 5.06M | 5.63M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 40K | 875K | 105K | 481K | 386K | -769K | 1.8M | 1.43M | 28.73M | -7.59M |
| Working Capital Changes | 10K | 1.01M | 132K | 569K | -663K | -138K | -509K | -8.17M | -7.33M | 678K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | -1.54M | -7.27M | -7.87M | -9.16M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -576K | -1.58M | 579K | -452K |
| Change in Payables | -54K | 611K | 177K | 580K | -41K | 0 | 0 | 0 | 0 | 2.63M |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 5.11M | 27.98M | 2.35M | -71K | 32.29M | 4.98M | 20.73M | 6.64M | -13.62M | -10.39M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 4.99M | 20.17M | 5M | -13M | 0 |
| Equity Issued (Net) | 5M | 27.38M | 0 | 0 | 31.97M | 0 | -194K | -78K | -176K | -9K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -194K | -78K | -176K | -9K |
| Other Financing | 108K | 594K | 2.35M | -71K | 322K | -8K | 753K | 1.72M | -439K | -10.38M |
| Net Change in Cash | 2.98M▲ 0% | 24.33M▲ 715.5% | -5.48M▼ 122.5% | -9.13M▼ 66.7% | 16.69M▲ 282.8% | -9.24M▼ 155.4% | 2.67M▲ 128.9% | -10.51M▼ 492.9% | 13.37M▲ 227.2% | -18.37M▲ 0% |
| Free Cash Flow | -2.12M▲ 0% | -3.64M▼ 71.4% | -7.83M▼ 114.9% | -9.06M▼ 15.8% | -15.6M▼ 72.1% | -14.22M▲ 8.8% | -18.06M▼ 27.0% | -17.14M▲ 5.1% | 26.98M▲ 257.4% | -7.99M▲ 0% |
| FCF Margin % | - | - | - | - | -9173.53% | - | -1224.95% | -80.67% | 56.75% | -20.59% |
| FCF Growth % | -14.07% | -71.42% | -114.94% | -15.77% | -72.13% | 8.8% | -26.97% | 5.07% | 257.38% | -133.84% |
| FCF per Share | -0.17 | -0.24 | -0.41 | -0.46 | -0.66 | -0.55 | -0.69 | -0.65 | 0.99 | 0.99 |
| FCF Conversion (FCF/Net Income) | 0.76x | 0.52x | 0.79x | 0.69x | 0.86x | 0.83x | 0.79x | 1.07x | -61.88x | 1.15x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
FENC Key Ratios
Fennec Pharmaceuticals Inc. (FENC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -135.45% | -46.47% | -41.14% | -78.78% | -88.46% | -76.68% | -344.99% | - | - | 117.12% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | -414.73% | - | 37.31% |
| Gross Margin | - | - | - | - | 100% | - | 94.4% | 94.08% | 93.3% | 93.12% |
| Net Margin | - | - | - | - | -10652.35% | - | -1544.89% | -75.5% | -0.92% | -17.89% |
| Debt / Equity | - | - | - | - | - | 0.32x | - | - | - | -4.03x |
| Interest Coverage | - | - | - | - | - | -135.49x | -22.18x | -3.76x | 0.63x | -1.57x |
| FCF Conversion | 0.76x | 0.52x | 0.79x | 0.69x | 0.86x | 0.83x | 0.79x | 1.07x | -61.88x | 1.15x |
| Revenue Growth | - | - | - | - | - | -100% | - | 1341.62% | 123.69% | -21.82% |
FENC SEC Filings & Documents
Fennec Pharmaceuticals Inc. (FENC) SEC filings — annual & quarterly reports (10-K, 10-Q)
FENC Frequently Asked Questions
Fennec Pharmaceuticals Inc. (FENC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Fennec Pharmaceuticals Inc. (FENC) reported $38.8M in revenue for fiscal year 2024. This represents a 3878999900% increase from $0.0M in 2000.
Fennec Pharmaceuticals Inc. (FENC) grew revenue by 123.7% over the past year. This is strong growth.
Fennec Pharmaceuticals Inc. (FENC) reported a net loss of $6.9M for fiscal year 2024.
Dividend & Returns
Fennec Pharmaceuticals Inc. (FENC) had negative free cash flow of $8.0M in fiscal year 2024, likely due to heavy capital investments.
Explore More FENC
Fennec Pharmaceuticals Inc. (FENC) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates